Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: Hospices Civils de Lyon
Prostate cancer is the third leading cause of cancer-related death in men in the United States and Europe. The treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved with the arrival of the radioligand \[177Lu\]Lu-PSMA-617, which specifically targets PSMA-expressing cancer cells. The randomized phase III VISION study showed that \[177Lu\]Lu-PSMA-617 significantly improved progression-free survival and overall survival with an acceptable toxicity profile. The ReaLuP study will evaluate the efficacy of a re-treatment of \[177Lu\]Lu-PSMA-617 in patients with progressive PSMA-positive mCRPC and who have been previously treated with \[177Lu\]Lu-PSMA without evidence of progression during this first course of treatment. Patients will be treated until disease progression, unacceptable toxicity or death, or alternatively up to 9 months after the last dose of treatment. At the end of this follow up period, patients will enter the " long term follow up ", at least for 2 years after the end of the last active follow-up.
This description comes directly from the study's public registry record.
Denis MAILLET, Prof; MD/PhD · 04 78 86 43 85 · Denis.maillet@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| Médecine Nucléaire, Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Oncologie Médicale, CHU Brest-Hôpital Morvan | Brest, France | Not Yet Recruiting |
| Hôpital Louis Pradel, Hospices Civils de Lyon | Bron, France | Not Yet Recruiting |
| Oncologie Médicale, Centre François Baclesse | Caen, France | Not Yet Recruiting |
| Oncologie Médicale, Centre Jean Perrin | Clermont-Ferrand, France | Not Yet Recruiting |
| Médecine Nucléaire, Centre Hospitalier de Grenoble Alpes | Grenoble, France | Not Yet Recruiting |
| Médecine Nucléaire, Centre Léon Berard | Lyon, France | Not Yet Recruiting |
| Médecine Nucléaire, CHU de Nantes Hôtel-Dieu | Nantes, France | Not Yet Recruiting |
| Oncologie Médicale, Centre Antoine Lacassagne | Nice, France | Not Yet Recruiting |
| Institut de cancérologie du Gard | Nîmes, France | Not Yet Recruiting |
| Oncologie Médicale, Centre Hospitalier Lyon Sud, HCL | Pierre-Bénite, France | Recruiting |
| Oncologie Médicale, Centre Henri Becqueret | Rouen, France | Not Yet Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06866938